— Results from the phase IIb study, EMBRACE, demonstrate that N6LS, a bNAb administered every four months, effectively maintained undetectable viral load when combined with cabotegravir long-acting (CAB LA)
— Results add to the growing body of evidence that N6LS is a potent antiviral that can function as a component of a complete antiretroviral regimen
— EMBRACE study to continue investigating a combination of N6LS dosed at six months with CAB LA
Read the full company press release here.
SEE ALSO:
- Life4me+: N6LS antibody brings us closer to long-acting HIV treatment
- aidsmap: Broadly neutralising antibody N6LS could be part of long-acting HIV treatment
Source : ViiV Healthcare
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.